MCID: PNC041
MIFTS: 51

Pancreatic Ductal Adenocarcinoma

Categories: Cancer diseases, Endocrine diseases

Aliases & Classifications for Pancreatic Ductal Adenocarcinoma

MalaCards integrated aliases for Pancreatic Ductal Adenocarcinoma:

Name: Pancreatic Ductal Adenocarcinoma 12 15 17 71
Ductal Adenocarcinoma of the Pancreas 12

Classifications:



External Ids:

Disease Ontology 12 DOID:3498
NCIt 49 C9120
UMLS 71 C1335302

Summaries for Pancreatic Ductal Adenocarcinoma

Disease Ontology : 12 A pancreatic adenocarcinoma that derives from pancreatic duct cells.

MalaCards based summary : Pancreatic Ductal Adenocarcinoma, also known as ductal adenocarcinoma of the pancreas, is related to pancreatic cancer and cholangiocarcinoma, and has symptoms including pruritus, abdominal pain and icterus. An important gene associated with Pancreatic Ductal Adenocarcinoma is MIR155 (MicroRNA 155), and among its related pathways/superpathways is LncRNA-mediated mechanisms of therapeutic resistance. The drugs Hyaluronic acid and Calcium, Dietary have been mentioned in the context of this disorder. Affiliated tissues include Pancreas, t cells and lymph node.

Related Diseases for Pancreatic Ductal Adenocarcinoma

Diseases related to Pancreatic Ductal Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(showing 241, show less)
# Related Disease Score Top Affiliating Genes
1 pancreatic cancer 33.3 UCA1 PVT1 MIR21 MIR155 MALAT1 LINC00673
2 cholangiocarcinoma 31.5 UCA1 MIR21 MALAT1 H19 DAPK1 AFAP1-AS1
3 retinitis pigmentosa 11 31.1 UCA1 PVT1 HOTAIR
4 lung cancer susceptibility 3 31.1 MIR31HG MIR21 MALAT1 HOTAIR H19 DAPK1
5 b-cell lymphoma 31.0 PVT1 MIR21 MIR155 MALAT1 HOTAIR DAPK1
6 kidney cancer 30.8 PVT1 MIR21 MALAT1 HOTAIR H19 DAPK1
7 renal cell carcinoma, nonpapillary 30.8 UCA1 PVT1 MIR21 MIR155 MALAT1 HOTAIR
8 gastrointestinal system cancer 30.8 MIR21 MIR155 MALAT1 HOTAIR H19
9 small cell cancer of the lung 30.7 MIR21 MALAT1 HOTTIP HOTAIR
10 gallbladder cancer 30.7 UCA1 MALAT1 HOTAIR H19 AFAP1-AS1
11 osteogenic sarcoma 30.7 UCA1 TUSC7 PVT1 MALAT1 HOTTIP HOTAIR
12 hepatocellular carcinoma 30.7 UCA1 TUSC7 PVT1 MIR21 MIR155 MALAT1
13 esophageal cancer 30.6 UCA1 PVT1 MIR21 MIR155 MALAT1 HOTTIP
14 nasopharyngeal carcinoma 30.5 PVT1 MIR21 MALAT1 HOTAIR H19 DAPK1
15 leukemia, acute myeloid 30.5 UCA1 TUSC7 MIR21 MIR155 MALAT1 HOTAIRM1
16 clear cell renal cell carcinoma 30.5 PVT1 MIR21 MIR155 MALAT1
17 pituitary adenoma 30.5 MALAT1 HOTAIR H19
18 gastric cancer 30.0 UCA1 TUSC7 TMEM238L PVT1 MIR31HG MIR21
19 colorectal cancer 29.6 UCA1 TUSC7 TMEM238L PVT1 MIR31HG MIR21
20 adenocarcinoma 11.6
21 pancreatic cancer 5 11.5
22 pancreatic adenocarcinoma 11.0
23 pancreatitis 10.8
24 pancreas disease 10.7
25 pancreatic agenesis 1 10.7
26 pancreatic ductal carcinoma 10.7
27 autoimmune pancreatitis 10.7
28 polymyositis 10.6 MIR21 MIR155
29 microvascular complications of diabetes 3 10.6 PVT1 MIR21 MALAT1
30 intrahepatic cholangiocarcinoma 10.6
31 severe combined immunodeficiency 10.6
32 laryngeal squamous cell carcinoma 10.6 MIR21 MIR155 MALAT1 HOTAIR H19
33 triple-receptor negative breast cancer 10.6 MALAT1 HOTAIR
34 thyroid cancer, nonmedullary, 1 10.5 MALAT1 HOTTIP HOTAIR H19
35 neutropenia 10.5
36 vulva squamous cell carcinoma 10.5 MIR31HG MALAT1
37 oral squamous cell carcinoma 10.5 UCA1 MIR21 MIR155 MALAT1 HOTAIR H19
38 myeloma, multiple 10.5 UCA1 PVT1 MIR21 MALAT1 HOTAIR H19
39 tongue disease 10.5 UCA1 MIR21 LINC00673
40 lymphoma, hodgkin, classic 10.5 PVT1 MIR21 MIR155
41 bladder urothelial carcinoma 10.5 UCA1 PVT1 MALAT1 HOTAIR
42 esophagus squamous cell carcinoma 10.5 HOTAIR AFAP1-AS1
43 pancreatitis, hereditary 10.5
44 neuroendocrine tumor 10.5
45 acute pancreatitis 10.5
46 glioma susceptibility 1 10.5 TUSC7 MIR21 MALAT1 HOTAIRM1 HOTAIR H19
47 glioma 10.4 UCA1 PVT1 MIR21 MALAT1 HOTTIP HOTAIR
48 obstructive jaundice 10.4
49 hypoxia 10.4
50 tongue squamous cell carcinoma 10.4 UCA1 MIR21 MALAT1 LINC00673 HOTTIP AFAP1-AS1
51 coronary heart disease 1 10.4 MIR155 HOTTIP H19
52 astrocytoma 10.4 UCA1 TUSC7 PVT1 MIR21 HOTAIRM1 HOTAIR
53 cystadenoma 10.4
54 adenosquamous carcinoma 10.4
55 thyroid gland cancer 10.4 UCA1 PVT1 MALAT1 HOTAIR H19 DAPK1
56 miyoshi muscular dystrophy 1 10.4 MIR21 MIR155
57 squamous cell carcinoma 10.3 UCA1 TUSC7 MALAT1 HOTAIR H19 DAPK1
58 lynch syndrome 10.3
59 tubular adenocarcinoma 10.3
60 in situ carcinoma 10.3
61 diabetes mellitus 10.3
62 cytokine deficiency 10.3
63 malignant glioma 10.3 TUSC7 PVT1 MALAT1 HOTTIP HOTAIRM1 HOTAIR
64 cervical cancer 10.3 UCA1 PVT1 MIR31HG MIR21 MIR155 MALAT1
65 melanoma 10.3 UCA1 PVT1 MALAT1 LINC00673 HOTAIRM1 HOTAIR
66 prostate cancer 10.3
67 wilms tumor 5 10.3
68 duodenum adenocarcinoma 10.3
69 pancreatic endocrine carcinoma 10.3
70 neuroendocrine carcinoma 10.3
71 ovarian serous cystadenocarcinoma 10.3
72 bladder cancer 10.3 UCA1 PVT1 MIR31HG MIR21 MALAT1 HOTAIR
73 fibrosis of extraocular muscles, congenital, 1 10.2
74 retinoblastoma 10.2
75 familial adenomatous polyposis 10.2
76 exanthem 10.2
77 hyperinsulinism 10.2
78 bilirubin metabolic disorder 10.2
79 tic disorder 10.2
80 acinar cell carcinoma 10.2
81 hyperglycemia 10.2
82 familial retinoblastoma 10.2
83 47,xyy 10.2
84 acute sensory ataxic neuropathy 10.2
85 neuroendocrine neoplasm of pancreas 10.2
86 fatty liver disease 10.2 MIR21 MIR155 MALAT1
87 autoimmune disease 10.1
88 pancreas, annular 10.1
89 peutz-jeghers syndrome 10.1
90 wilms tumor 1 10.1
91 ataxia-telangiectasia 10.1
92 multinucleated neurons, anhydramnios, renal dysplasia, cerebellar hypoplasia, and hydranencephaly 10.1
93 body mass index quantitative trait locus 11 10.1
94 body mass index quantitative trait locus 9 10.1
95 body mass index quantitative trait locus 8 10.1
96 gastrointestinal stromal tumor 10.1
97 body mass index quantitative trait locus 4 10.1
98 body mass index quantitative trait locus 10 10.1
99 body mass index quantitative trait locus 7 10.1
100 body mass index quantitative trait locus 12 10.1
101 body mass index quantitative trait locus 14 10.1
102 pancreatic cancer 4 10.1
103 body mass index quantitative trait locus 18 10.1
104 body mass index quantitative trait locus 19 10.1
105 body mass index quantitative trait locus 20 10.1
106 thrombosis 10.1
107 portal vein thrombosis 10.1
108 choledocholithiasis 10.1
109 telangiectasis 10.1
110 diarrhea 10.1
111 islet cell tumor 10.1
112 hepatitis b 10.1
113 gastric adenocarcinoma 10.1
114 pancreatic serous cystadenoma 10.1
115 avian influenza 10.1
116 bile duct cancer 10.1
117 lymphopenia 10.1
118 thyroid hyalinizing trabecular adenoma 10.1
119 adenoma 10.1
120 gastrointestinal system disease 10.1
121 cholangitis 10.1
122 pulmonary embolism 10.1
123 stomatitis 10.1
124 back pain 10.1
125 autoimmune pancreatitis type 1 10.1
126 rare tumor 10.1
127 polyploidy 10.1
128 mesothelioma, malignant 10.0
129 ovarian cancer 10.0
130 pancreatic cancer 3 10.0
131 zollinger-ellison syndrome 10.0
132 anthracosilicosis 10.0
133 benign giant cell tumor 10.0
134 signet ring cell adenocarcinoma 10.0
135 mucinous cystadenocarcinoma 10.0
136 lymph node disease 10.0
137 aortic aneurysm, familial abdominal, 1 10.0
138 alcohol dependence 10.0
139 breast cancer 10.0
140 diabetes mellitus, noninsulin-dependent 10.0
141 multiple endocrine neoplasia, type i 10.0
142 gastric cancer, hereditary diffuse 10.0
143 myhre syndrome 10.0
144 thoracolaryngopelvic dysplasia 10.0
145 thrombophilia due to thrombin defect 10.0
146 tuberous sclerosis 1 10.0
147 congenital heart defects, hamartomas of tongue, and polysyndactyly 10.0
148 cystic fibrosis 10.0
149 leprosy 3 10.0
150 proteasome-associated autoinflammatory syndrome 1 10.0
151 pituitary hormone deficiency, combined, 2 10.0
152 sjogren syndrome 10.0
153 thrombocytopenia 3 10.0
154 thymoma, familial 10.0
155 squamous cell carcinoma, head and neck 10.0
156 wiskott-aldrich syndrome 10.0
157 ataxia and polyneuropathy, adult-onset 10.0
158 panbronchiolitis, diffuse 10.0
159 body mass index quantitative trait locus 1 10.0
160 endometrial cancer 10.0
161 human immunodeficiency virus type 1 10.0
162 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 10.0
163 seborrhea-like dermatitis with psoriasiform elements 10.0
164 fatty liver disease, nonalcoholic 1 10.0
165 prostate cancer, hereditary, 2 10.0
166 pachyonychia congenita 3 10.0
167 diarrhea 9 10.0
168 inflammatory bowel disease 10.0
169 polycystic liver disease 10.0
170 sleep apnea 10.0
171 limb ischemia 10.0
172 colorectal adenocarcinoma 10.0
173 gastrointestinal carcinoma 10.0
174 lymphoma 10.0
175 mucositis 10.0
176 polycystic kidney disease 10.0
177 cholelithiasis 10.0
178 glucose intolerance 10.0
179 portal hypertension 10.0
180 microcephaly 10.0
181 sarcoma 10.0
182 diphtheria 10.0
183 allergic hypersensitivity disease 10.0
184 tuberous sclerosis 10.0
185 polyneuropathy 10.0
186 thrombocytopenia 10.0
187 rectum cancer 10.0
188 neuroma 10.0
189 constipation 10.0
190 thrombophilia 10.0
191 benign mesothelioma 10.0
192 breast ductal carcinoma 10.0
193 acute kidney failure 10.0
194 mucinous adenocarcinoma 10.0
195 glioblastoma multiforme 10.0
196 interstitial lung disease 10.0
197 cystadenocarcinoma 10.0
198 multiple endocrine neoplasia 10.0
199 thymoma 10.0
200 fibrosarcoma 10.0
201 duodenal obstruction 10.0
202 appendix adenocarcinoma 10.0
203 aortic aneurysm 10.0
204 plasmacytoma 10.0
205 insulinoma 10.0
206 pancreatic cystadenoma 10.0
207 spindle cell sarcoma 10.0
208 carcinosarcoma 10.0
209 hypokalemia 10.0
210 liver cirrhosis 10.0
211 pancreatic adenosquamous carcinoma 10.0
212 hereditary breast ovarian cancer syndrome 10.0
213 peripheral nervous system disease 10.0
214 pancreatic acinar cell adenocarcinoma 10.0
215 distal biliary tract carcinoma 10.0
216 pancreatoblastoma 10.0
217 peptic ulcer disease 10.0
218 end stage renal disease 10.0
219 influenza 10.0
220 lung disease 10.0
221 neuropathy 10.0
222 autosomal dominant polycystic kidney disease 10.0
223 hypoglycemia 10.0
224 48,xyyy 10.0
225 chromosomal triplication 10.0
226 diffuse gastric cancer 10.0
227 glucagonoma 10.0
228 hansen's disease 10.0
229 pancreatic adenoma 10.0
230 splenomegaly 10.0
231 triploidy 10.0
232 aneurysm 10.0
233 pituitary tumors 10.0
234 posttransplant acute limbic encephalitis 10.0
235 rapidly involuting congenital hemangioma 10.0
236 acinar cell carcinoma of pancreas 10.0
237 argyria 10.0
238 pik3ca-related overgrowth syndrome 10.0
239 discoid lupus erythematosus 10.0
240 adenoma of pancreas 10.0
241 lung cancer 9.8 UCA1 TUSC7 PVT1 MIR31HG MIR21 MIR155

Graphical network of the top 20 diseases related to Pancreatic Ductal Adenocarcinoma:



Diseases related to Pancreatic Ductal Adenocarcinoma

Symptoms & Phenotypes for Pancreatic Ductal Adenocarcinoma

UMLS symptoms related to Pancreatic Ductal Adenocarcinoma:


pruritus, abdominal pain, icterus

Drugs & Therapeutics for Pancreatic Ductal Adenocarcinoma

Drugs for Pancreatic Ductal Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(showing 149, show less)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Hyaluronic acid Approved, Vet_approved Phase 3 9004-61-9 53477741
2 Calcium, Dietary Phase 3
3
asparaginase Phase 3
4 glucocorticoids Phase 3
5 N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide Phase 3
6
Calcium Nutraceutical Phase 3 7440-70-2 271
7
Doxorubicin Approved, Investigational Phase 2 23214-92-8 31703
8
Enoxaparin Approved Phase 2 9005-49-6 772
9
Dexamethasone Approved, Investigational, Vet_approved Phase 2 50-02-2 5743
10
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 2 1177-87-3
11
Capecitabine Approved, Investigational Phase 2 154361-50-9 60953
12
Fludarabine Approved Phase 2 21679-14-1, 75607-67-9 30751
13
Dimethyl sulfoxide Approved, Vet_approved Phase 2 67-68-5 679
14
nivolumab Approved Phase 2 946414-94-4
15
Niraparib Approved, Investigational Phase 1, Phase 2 1038915-60-4 24958200
16
Ipilimumab Approved Phase 1, Phase 2 477202-00-9
17
Atezolizumab Approved, Investigational Phase 1, Phase 2 1380723-44-3
18
Romidepsin Approved, Investigational Phase 1, Phase 2 128517-07-7 5352062
19
Lenalidomide Approved Phase 1, Phase 2 191732-72-6 216326
20
Azacitidine Approved, Investigational Phase 1, Phase 2 320-67-2 9444
21
Celecoxib Approved, Investigational Phase 2 169590-42-5 2662
22
Talazoparib Approved, Investigational Phase 2 1207456-01-6 135565082
23
Propofol Approved, Investigational, Vet_approved Phase 2 2078-54-8 4943
24
Cyclophosphamide Approved, Investigational Phase 1, Phase 2 50-18-0, 6055-19-2 2907
25
Carboplatin Approved Phase 1, Phase 2 41575-94-4 10339178 38904 498142
26
Pemetrexed Approved, Investigational Phase 1, Phase 2 137281-23-3, 150399-23-8 60843 446556
27
Coal tar Approved Phase 1, Phase 2 8007-45-2
28
leucovorin Approved Phase 2 58-05-9 6006 143
29
Levoleucovorin Approved, Investigational Phase 2 68538-85-2
30
Metformin Approved Phase 2 657-24-9 14219 4091
31
Adenosine Approved, Investigational Phase 2 58-61-7 60961
32
Olaparib Approved Phase 2 763113-22-0 23725625
33
Tegafur Approved, Investigational Phase 2 17902-23-7 5386
34
Durvalumab Approved, Investigational Phase 2 1428935-60-7
35
Bevacizumab Approved, Investigational Phase 1, Phase 2 216974-75-3
36
Cetuximab Approved Phase 2 205923-56-4 56842117 2333
37
Folic acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
38
Cediranib Investigational Phase 2 288383-20-0 9933475
39 Misonidazole Investigational Phase 2 13551-87-6
40
Maleic acid Experimental, Investigational Phase 2 110-17-8, 110-16-7 444972
41
Tremelimumab Investigational Phase 2 745013-59-6
42 Fibrinolytic Agents Phase 2
43 Hormones Phase 2
44
Liposomal doxorubicin Phase 2 31703
45 Antineoplastic Agents, Hormonal Phase 2
46 Antiemetics Phase 2
47 Hormone Antagonists Phase 2
48 Anticoagulants Phase 2
49 acivicin Phase 2
50 Liver Extracts Phase 2
51 Analgesics, Non-Narcotic Phase 2
52 Cyclooxygenase Inhibitors Phase 2
53 Analgesics Phase 2
54 Anti-Inflammatory Agents Phase 2
55 Anti-Inflammatory Agents, Non-Steroidal Phase 2
56 Anti-Bacterial Agents Phase 1, Phase 2
57 Antibiotics, Antitubercular Phase 1, Phase 2
58 Mitogens Phase 2
59 Interleukin-2 Phase 2
60 Cyclooxygenase 2 Inhibitors Phase 2
61 Antiprotozoal Agents Phase 2
62 Antiparasitic Agents Phase 2
63 Anesthetics Phase 2
64 Paraproteins Phase 1, Phase 2
65 Myeloma Proteins Phase 1, Phase 2
66 Antidotes Phase 1, Phase 2
67 Vitamin B Complex Phase 1, Phase 2
68 Antirheumatic Agents Phase 1, Phase 2
69 Alkylating Agents Phase 1, Phase 2
70 Folic Acid Antagonists Phase 1, Phase 2
71 Immunotoxins Phase 1, Phase 2
72 Antibodies, Monoclonal Phase 2
73 Vaccines Phase 2
74 Folate Phase 2
75 Vitamin B9 Phase 2
76 Hypoglycemic Agents Phase 2
77 Poly(ADP-ribose) Polymerase Inhibitors Phase 2
78 Complement System Proteins Phase 2
79 Immunoglobulins, Intravenous Phase 2
80 Immunoglobulin G Phase 2
81 Angiotensin Receptor Antagonists Phase 1, Phase 2
82 Immunoglobulins Phase 2
83 Antibodies Phase 2
84 Angiogenesis Inhibitors Phase 1, Phase 2
85 Gastrointestinal Agents Phase 2
86
Etoposide Approved Phase 1 33419-42-0 36462
87
Palbociclib Approved, Investigational Phase 1 571190-30-2 5005498 11431660 5330286
88
Tocopherol Approved, Investigational Phase 1 1406-66-2, 54-28-4 14986
89
Angiotensin II Approved, Investigational Phase 1 4474-91-3, 11128-99-7, 68521-88-0 172198
90
Losartan Approved Phase 1 114798-26-4 3961
91
Talimogene laherparepvec Approved, Experimental, Investigational Phase 1 1187560-31-1
92
Tofacitinib Approved, Investigational Phase 1 477600-75-2
93
Imiquimod Approved, Investigational Phase 1 99011-02-6 57469
94
afatinib Approved Phase 1 439081-18-2, 850140-72-6 10184653
95
Decitabine Approved, Investigational Phase 1 2353-33-5 451668
96
Povidone Approved Phase 1 9003-39-8
97
Idelalisib Approved Phase 1 870281-82-6
98
Vitamin E Approved, Nutraceutical, Vet_approved Phase 1 59-02-9 14985
99
Tyrosine Approved, Investigational, Nutraceutical Phase 1 60-18-4 6057
100
Threonine Approved, Nutraceutical Phase 1 72-19-5 6288
101
Vitamin D Approved, Nutraceutical, Vet_approved Phase 1 1406-16-2
102
Asparagine Approved, Investigational, Nutraceutical Phase 1 70-47-3 6267
103 Tocotrienol Investigational Phase 1 6829-55-6
104
Imidazole Experimental, Investigational Phase 1 288-32-4 795
105 Interleukin 1 Receptor Antagonist Protein Phase 1
106 Hematinics Phase 1
107 Etoposide phosphate Phase 1
108 neurokinin A Phase 1
109
Substance P Phase 1 33507-63-0 44359816
110 Tocotrienols Phase 1
111 Tocopherols Phase 1
112 Cola Phase 1
113 Poly ICLC Phase 1
114 Calciferol Phase 1
115 Angiotensin II Type 1 Receptor Blockers Phase 1
116 Angiotensinogen Phase 1
117 Antihypertensive Agents Phase 1
118 Anti-Arrhythmia Agents Phase 1
119 Giapreza Phase 1
120 interferons Phase 1
121 Adjuvants, Immunologic Phase 1
122
Serine Investigational, Nutraceutical Phase 1 56-45-1 5951
123
tannic acid Approved 1401-55-4
124
Benzocaine Approved, Investigational 94-09-7, 1994-09-7 2337
125
Aspirin Approved, Vet_approved 50-78-2 2244
126
Bethanechol Approved Early Phase 1 674-38-4 2370
127
Iron Approved, Experimental 15438-31-0, 7439-89-6 27284 23925
128
Epinephrine Approved, Vet_approved 51-43-4 5816
129
Racepinephrine Approved 329-65-7 838
130
carbamide peroxide Approved Early Phase 1 124-43-6
131
Sulforaphane Investigational 142825-10-3, 4478-93-7 5350
132
Trichostatin A Experimental 58880-19-6
133
Butyric Acid Experimental, Investigational Early Phase 1 107-92-6 264
134 Sulforafan
135 Calamus
136 Adrenergic beta-Antagonists
137 Angiotensin-Converting Enzyme Inhibitors
138 Hydroxymethylglutaryl-CoA Reductase Inhibitors
139
protease inhibitors
140 Platelet Aggregation Inhibitors
141 HIV Protease Inhibitors
142 Antipyretics
143 Neurotransmitter Agents Early Phase 1
144 Narcotics
145 Cholinergic Agents Early Phase 1
146 Muscarinic Agonists Early Phase 1
147 Radiopharmaceuticals Early Phase 1
148 Epinephryl borate
149
Ethylene Early Phase 1 74-85-1 6325

Interventional clinical trials:

(showing 239, show less)
# Name Status NCT ID Phase Drugs
1 The Effect of Gemcitabine Plus Nab-paclitaxel as Secondary Chemotherapy in Advanced Pancreatic Cancer Unknown status NCT03401827 Phase 4 Chemotherapy (Gemcitabine + nab-paclitaxel)
2 Prevention of Upper Gastrointestinal Hemorrhage Using Albis® in the Patients of Locally Advanced Pancreatic Cancer Who Underwent Concurrent Chemoradiotherapy Withdrawn NCT02570529 Phase 4 Albis®;Placebo
3 A Randomized, Phase 3 Study of Eryaspase in Combination With Chemotherapy Versus Chemotherapy Alone as 2nd-Line Treatment of Patients With Pancreatic Adenocarcinoma Recruiting NCT03665441 Phase 3 eryaspase;Gemcitabine plus Abraxane;Irinotecan plus 5-FU plus leucovorin
4 Nordic Multicentre Un-blinded Phase II Randomized Controlled Trial (RCT) Evaluating the Additional Efficacy of Adding Chemotherapy Prior to Resection of a Pancreatic Head Malignancy to Avoid Early Mortality in Those Ultimately Resected Recruiting NCT02919787 Phase 2, Phase 3 5-FU;Oxaliplatine;Irinotecan;5-FU;Oxaliplatine;Irinotecan
5 A Randomized, Multicenter, Controlled, Unblinded Study to Assess the Safety and Efficacy of the NanoKnife® System for the Ablation of Unresectable Stage 3 Pancreatic Adenocarcinoma Recruiting NCT03899636 Phase 3 Modified FOLFIRINOX Regimen
6 A Phase III Study of BBI-608 Plus Nab-Paclitaxel With Gemcitabine in Adult Patients With Metastatic Pancreatic Adenocarcinoma Active, not recruiting NCT02993731 Phase 3 Napabucasin;Nab-paclitaxel;Gemcitabine
7 A Phase 3 Study of Relacorilant in Combination With Nab-Paclitaxel in Patients With Metastatic Pancreatic Ductal Adenocarcinoma (RELIANT) Not yet recruiting NCT04329949 Phase 3 Relacorilant, 100 mg and 25 mg;Nab paclitaxel
8 Mesenteric Approach vs. Conventional Approach for Pancreatic Cancer During Pancreaticoduodenectomy (MAPLE-PD Trial) Not yet recruiting NCT03317886 Phase 3
9 A Phase III Randomized Study Evaluating Gemcitabine and Paclitaxel Versus Gemcitabine Alone After FOLFIRINOX Failure or Intolerance in Metastatic Pancreatic Ductal Adenocarcinoma Suspended NCT03943667 Phase 3 Gemcitabine;Paclitaxel
10 A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Gemcitabine and Nab-paclitaxel Combined With Momelotinib in Subjects With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma Preceded by a Dose-finding, Lead-in Phase Terminated NCT02101021 Phase 3 Momelotinib;Placebo to match momelotinib;Nab-paclitaxel;Gemcitabine
11 A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) in Combination With Nab-Paclitaxel Plus Gemcitabine Compared With Placebo Plus Nab-Paclitaxel and Gemcitabine in Subjects With Hyaluronan-High Stage IV Previously Untreated Pancreatic Ductal Adenocarcinoma Terminated NCT02715804 Phase 3 Placebo;nab-Paclitaxel;Gemcitabine
12 Phase II Trial of Nab-paclitaxel Plus Gemcitabine in First-line Treatment of Chinese Patients With Advanced Pancreatic Cancer Unknown status NCT02135822 Phase 2 nanoparticle albumin-bound paclitaxel;gemcitabine
13 Phase II Trial of Nab-paclitaxel Plus S-1 in First-line Treatment of Patients With Advanced Pancreatic Cancer Unknown status NCT02124317 Phase 2 nanoparticle albumin-bound paclitaxel;S-1
14 A Phase II, Single Arm, Open Label Study to Evaluate the Efficacy and Safety of the Combination of S-1, Irinotecan and Oxaliplatin (SIRIOX) in Treating Patients With Advanced Inoperable or Metastatic Pancreatic Cancer Unknown status NCT03403101 Phase 2 S1;Oxaliplatin;Irinotecan
15 PHASE II Study - EFFICACY AND SAFETY OF PARPi TO TREAT PANCREATIC CANCER Unknown status NCT02511223 Phase 2 OLAPARIB
16 A Phase Ib and II Open-Label, Multi-Center Study of MEDI4736 Evaluated in Different Combinations in Patients With Metastatic Pancreatic Ductal Adenocarcinoma Completed NCT02583477 Phase 1, Phase 2 MEDI4736 in combination with nab-paclitaxel and gemcitabine;MEDI4736 in combination with AZD5069
17 A Phase II Open-Label, Multi-Center Study of MEDI4736 Evaluated as Single Agent or in Combination With Tremelimumab in Patients With Metastatic Pancreatic Ductal Adenocarcinoma Completed NCT02558894 Phase 2 MEDI4736 monotherapy;tremelimumab+MEDI4736
18 An Adaptive, Open-Label, Randomized Phase 2 Study of Abemaciclib as a Monotherapy and in Combination With Other Agents Versus Choice of Standard of Care (Gemcitabine or Capecitabine) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma Completed NCT02981342 Phase 2 Abemaciclib;LY3023414;Gemcitabine;Capecitabine
19 A 3-Arm Phase 2 Double-Blind Randomized Study of Gemcitabine, Abraxane® Plus Placebo Versus Gemcitabine, Abraxane® Plus 1 or 2 Truncated Courses of Demcizumab in Subjects With 1st-Line Metastatic Pancreatic Ductal Adenocarcinoma Completed NCT02289898 Phase 2 Demcizumab;Abraxane®;gemcitabine;Placebo
20 A Phase 1b/2 Pilot Trial of Nab-Paclitaxel Plus Cisplatin Plus Gemcitabine (Nabplagem) in Patients With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma (PDA) Completed NCT01893801 Phase 1, Phase 2 nab-paclitaxel;Cisplatin;gemcitabine
21 Capecitabine and Oxaliplatin in Patients With Advanced or Metastatic Pancreatic Adenocarcinoma Completed NCT00585078 Phase 2 Capecitabine;Oxaliplatin
22 Modified FOLFIRINOX for Gemcitabine Refractory Pancreatic Cancer: A Phase II Multicenter Trial Completed NCT02440958 Phase 2 modified FOLFIRINOX regimen
23 A Multicenter, Open-Label Pilot Phase 2 Study to Investigate the Preliminary Efficacy and Safety of INNO-206 (Doxorubicin-EMCH) in Subjects With Advanced or Unresectable Pancreatic Ductal Carcinoma Whose Tumors Have Progressed Following Prior Treatment With Gemcitabine and Fluoropyrimidine-Based Chemotherapy Completed NCT01580397 Phase 2 INNO-206
24 Randomised Phase II Trial to Investigate Two Different Schedules of Nab-paclitaxel (Abraxane) Combined With Gemcitabine as First Line Treatment for Metastatic Pancreatic Ductal Adenocarcinoma Completed NCT03529175 Phase 2 Abraxane (nab-paclitaxel);Gemcitabine
25 A Study of ARRY-382 in Combination With Pembrolizumab, a Programmed Cell Death Receptor 1 (PD-1) Antibody, for the Treatment of Patients With Advanced Solid Tumors Completed NCT02880371 Phase 1, Phase 2 ARRY-382;Pembrolizumab
26 A Phase 2, Randomized, Multicenter Study of PEGPH20 (PEGylated Recombinant Human Hyaluronidase) Combined With Nab-Paclitaxel Plus Gemcitabine Compared With Nab-Paclitaxel Plus Gemcitabine in Subjects With Stage IV Previously Untreated Pancreatic Cancer Completed NCT01839487 Phase 2 PEGPH20;Nab-paclitaxel;Gemcitabine;Dexamethasone;Enoxaparin
27 A PHASE Ib/IIa STUDY OF COMBINATION THERAPY WITH GEMCITABINE AND ATU027 IN SUBJECTS WITH LOCALLY ADVANCED OR METASTATIC PANCREATIC ADENOCARCINOMA Completed NCT01808638 Phase 1, Phase 2 Atu027 & gemcitabine in lead in safety period;Atu027 & gemcitabine in treatment arm 1;Atu027 & gemcitabine in treatment arm 2
28 A Phase II Study of S-1 in Combination With Gemcitabine and Erlotinib in Patients With Advanced or Metastatic Pancreatic Cancer Completed NCT01693419 Phase 2 GES (Gemcitabine, Erlotinib, S-1)
29 A Pilot Study of Neoadjuvant and Adjuvant mFOLFIRINOX in Localized, Resectable Pancreatic Adenocarcinoma Completed NCT01660711 Phase 2 5 Fluorouracil;Leucovorin;Irinotecan;Oxaliplatin
30 A Phase II Trial of Nab-Paclitaxel Plus Cisplatin Plus Gemcitabine in Patients With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma Recruiting NCT03915444 Phase 2 nab-Paclitaxel + Cisplatin + Gemcitabine
31 Phase 2 Study Evaluating the Efficacy,Safety,Tolerability and PK of siG12D-LODER in the Treatment of Patients With Unresectable LAPC When Used in Conjunction With Standard Chemotherapy (Gemcitabine+Nab-Paclitaxel) Versus Chemotherapy Alone Recruiting NCT01676259 Phase 2 siG12D-LODER;Gemcitabine+nab-Paclitaxel
32 A Randomized Phase II Study of Pembrolizumab With or Without Defactinib, a Focal Adhesion Kinase Inhibitor Following Chemotherapy as a Neoadjuvant and Adjuvant Treatment for Resectable Pancreatic Ductal Adenocarcinoma (PDAC) Recruiting NCT03727880 Phase 2 Pembrolizumab;Defactinib
33 A Randomized Non-comparative Phase II Study of Maintenance Therapy With OSE2101 Vaccine Alone or in Combination With Nivolumab, or FOLFIRI After Induction Therapy With FOLFIRINOX in Patients With Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma (TEDOPaM - D17-01 PRODIGE 63 Study). Recruiting NCT03806309 Phase 2 FOLFIRI;OSE2101;Nivolumab
34 A Phase I/II Trial of Combination Immunotherapy With Nivolumab and a CCR2/CCR5 Dual Antagonist (BMS-813160) With or Without GVAX Following Chemotherapy and Radiotherapy for Locally Advanced Pancreatic Ductal Adenocarcinomas (PDACs). Recruiting NCT03767582 Phase 1, Phase 2 Nivolumab;CCR2/CCR5 dual antagonist;GVAX
35 Phase II Trial Comparing Nab-paclitaxel Plus S-1 Versus Nab-paclitaxel Plus Gemcitabine in First-line Treatment of Patients With Advanced Pancreatic Cancer Recruiting NCT03636308 Phase 2 nanoparticle albumin-bound paclitaxel;S1;Gemcitabine
36 Transabdominal Ultrasound With BR55 for Characterization of Pancreatic Lesions Recruiting NCT03486327 Phase 2 BR55
37 A Phase I/II Study to Evaluate the Tolerability and Efficacy of BMS-813160 (CCR2/5 Inhibitor) With Nivolumab and Gemcitabine and Nab-paclitaxel in Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC) Recruiting NCT03496662 Phase 1, Phase 2 BMS-813160;Nivolumab;Gemcitabine;Nab-paclitaxel
38 A Phase II Pilot Trial of Nivolumab + Albumin-Bound Paclitaxel + Paricalcitol + Cisplatin + Gemcitabine (NAPPCG) In Patients With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma Recruiting NCT02754726 Phase 2 Nivolumab;Albumin-bound paclitaxel;Paricalcitol;Cisplatin;Gemcitabine
39 PARPVAX: Parpvax: A Phase 1b/2, Open Label Study of Niraparib Plus Either Ipilimumab or Nivolumab in Patients With Advanced Pancreatic Cancer Whose Disease Has Not Progressed on Platinum-based Therapy Recruiting NCT03404960 Phase 1, Phase 2 Niraparib + Nivolumab;Niraparib + Ipilimumab
40 Evaluation of Polychemotherapy With XELOXIRI-3 in Elderly or Frail Patients With Metastatic Pancreatic Adenocarcinoma (ALIX) Recruiting NCT03974854 Phase 2 XELOXIRI-3;Gemcitabine
41 A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer) Recruiting NCT03193190 Phase 1, Phase 2 Nab-Paclitaxel;Gemcitabine;Oxaliplatin;Leucovorin;Fluorouracil;Atezolizumab;Cobimetinib;PEGPH20;BL-8040;Selicrelumab;Bevacizumab;RO6874281;AB928;Tiragolumab
42 A Phase II Trial to Assess the Evolution of KRAS Mutation Load by Liquid Biopsy in Patients With Resectable Pancreatic Ductal Adenocarcinoma Treated With Neoadjuvant NALIRINOX Recruiting NCT04010552 Phase 2 NALRINOX combination
43 A Multicenter, Phase I/II Study of Sequential Epigenetic and Immune Targeting in Combination With Nab-Paclitaxel/Gemcitabine in Patients With Advanced Pancreatic Ductal Adenocarcinoma. Recruiting NCT04257448 Phase 1, Phase 2 Romidepsin;Azacitidine;nab-Paclitaxel;Gemcitabine;Durvalumab;Lenalidomide capsule
44 A Phase II Pilot Trial Of Paclitaxel Protein Bound and Gemcitabine Based Chemotherapy and the Addition Of Paricalcitol Upon Attainment of Stable or Progressive Disease in Patients With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma Recruiting NCT04054362 Phase 2 Paclitaxel protein bound;Cisplatin;Gemcitabine;Paricalcitol
45 Perioperative Therapy for Resectable Pancreatic Adenocarcinoma and Borderline Resectable Pancreatic Adenocarcinoma With Molecular Correlates Recruiting NCT02723331 Phase 2 Nab-paclitaxel and gemcitabine for R-PDAC Patients;Nab-paclitaxel and gemcitabine for BR-PDAC Patients
46 An International Multicentre, Open-Label First in Human Phase I/II Study to Evaluate the Safety, Tolerability, Biodistribution and Antitumour Activity of 177Lu-3BP-227 for the Treatment of Subjects With Solid Tumours Expressing Neurotensin Receptor 1 Recruiting NCT03525392 Phase 1, Phase 2 177Lu-3BP-227 (also called 177Lu-IPN01087)
47 Clinical Study to Assess Efficacy and Safety of MDA-TIL (Autologous Expanded Tumor Infiltrating Lymphocytes) Across Multiple Tumor Types Recruiting NCT03610490 Phase 2 Cyclophosphamide;Fludarabine
48 Impact of Tumor and Stromal Subtypes on Efficacy of Neoadjuvant FOLFIRINOX in Subjects With Non-Metastatic Pancreatic Cancer Recruiting NCT03977233 Phase 2 Oxaliplatin;Leucovorin;Irinotecan Hydrochloride;5-FU
49 Gemcitabine and Celecoxib Combination Therapy in Treating Patients With R0 Resection Pancreatic Cancer Recruiting NCT03498326 Phase 2 Gemcitabine;Gemcitabine
50 A Health Service Research Study to Investigate Survival of Metastatic Pancreatic Cancer Patients After Sequential Chemotherapy: An AIO Phase II Cross Over Trial (PANTHEON) Recruiting NCT03331640 Phase 2 OFF;FOLFIRI Protocol
51 An Open-label, Multi-center, Phase 1b Study to Investigate the Safety and Tolerability of SLC-0111 (WBI-5111) in Combination With Gemcitabine in Metastatic Pancreatic Ductal Adenocarcinoma Subjects Positive for Carbonic Anhydrase IX Recruiting NCT03450018 Phase 1, Phase 2 SLC-0111;Gemcitabine Injection
52 Ultrasound-enhanced Uptake of Chemotherapy in Patients With Inoperable Pancreatic Ductal Adenocarcinoma - A Randomized Controlled Trial Recruiting NCT04146441 Phase 2 Chemotherapy
53 PRIMUS002: An Umbrella Phase II Study Examining Two Neo-adjuvant Regimens (FOLFOX-A and AG) in Resectable and Borderline Resectable Pancreatic Ductal AdenoCarcinoma (PDAC), Focusing on Biomarker and Liquid Biopsy Development Recruiting NCT04176952 Phase 2 FOLFOX-A;AG
54 A PHASE 1B/2 STUDY TO EVALUATE SAFETY AND CLINICAL ACTIVITY OF COMBINATIONS OF AVELUMAB, BINIMETINIB AND TALAZOPARIB IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC RAS-MUTANT SOLID TUMORS Recruiting NCT03637491 Phase 2 Avelumab;Binimetinib;Talazoparib
55 A Phase 2, Open-Label, Multicenter, Randomized Study Evaluating NEOadjuvant Immunotherapy Based Combinations in Patients With Resectable PANCreatic Ductal Adenocarcinoma Recruiting NCT03979066 Phase 2 Atezolizumab;PEGPH20
56 Phase II Study of PEGPH20 and Pembrolizumab (MK-3475) for Patients With Previously Treated Hyaluronan High (HA-High) Metastatic Pancreatic Ductal Adenocarcinoma Recruiting NCT03634332 Phase 2 PEGPH20
57 Phase IB/II Trial of High Dose Ascorbic Acid (AA) + Nanoparticle Paclitaxel Protein Bound + Cisplatin + Gemcitabine (AA NABPLAGEM) in Patients Who Have No Prior Therapy for Their Metastatic Pancreatic Cancer Recruiting NCT03410030 Phase 1, Phase 2 Ascorbic Acid;Paclitaxel protein-bound;Cisplatin;Gemcitabine
58 A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors Recruiting NCT02498613 Phase 2 Cediranib;Cediranib Maleate;Olaparib
59 Phase II Study of Neoadjuvant Chemotherapy of Gemcitabine+Nab-paclitaxel Therapy for Patients With Borderline Resectable Pancreatic Cancer Recruiting NCT02926183 Phase 2 Neoadjuvant chemotherapy of gemcitabine plus nab-paclitaxel
60 A Phase II Pilot Trial Of Paclitaxel Protein Bound Plus Cisplatin Plus Gemcitabine and the Addition Of Paricalcitol Upon Disease Progression in Patients With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma (NABPLAGEMD) Recruiting NCT03415854 Phase 2 Paricalcitol (Zemplar)
61 Multi-center, Open-label, Phase 1b Clinical Trial to Evaluate the Safety, Tolerability, and Exploratory Efficacy of TEW-7197 in Combination With FOLFOX in Patients With Metastatic Pancreatic Ductal Adenocarcinoma Who Have Failed First-Line Gemcitabine and Nab-Paclitaxel Recruiting NCT03666832 Phase 1, Phase 2 TEW-7197
62 Irreversible Electroporation (IRE) Followed by Nivolumab in Patients With Metastatic Pancreatic Cancer: a Multicenter Single-arm Phase II Trial Recruiting NCT04212026 Phase 2 Nivolumab
63 A Multicenter Randomized Phase II Study to Determine the Optimal First-line Chemotherapy Regimen in Patients With Metastatic Pancreatic Cancer Recruiting NCT03487016 Phase 2 Gemcitabine;Nab-paclitaxel;5-FU;Irinotecan Liposomal Injection;Oxaliplatin
64 An Open Label, Dose Escalation Followed by Dose Expansion, Safety and Tolerability Trial of CAN04, a Fully Humanized Monoclonal Antibody Against IL1RAP, in Subjects With Solid Malignant Tumors Recruiting NCT03267316 Phase 1, Phase 2 Cisplatin;Gemcitabine;Nab-paclitaxel
65 A Phase 2 Study to Evaluate the Safety and Efficacy of Nab-pacliatxel Plus Gemcitabine in Korean Patients With Metastatic Pancreatic Ductal Adenocarcinoma Recruiting NCT02426281 Phase 2 nab-paclitaxel;gemcitabine
66 A Phase I/IIA Study to Assess Safety, Tolerability and Preliminary Activity of the Combination of FAK (Defactinib) and PD-1 (Pembrolizumab) Inhibition in Patients With Advanced Solid Malignancies (FAK-PD1) Recruiting NCT02758587 Phase 1, Phase 2 Defactinib;Pembrolizumab
67 Phase II Open-Label, Single-Center Study Evaluating Safety and Efficacy of Pembrolizumab Following Induction With the Hypomethylating Agent Azacitidine in Patients With Advanced Pancreatic Cancer After Failure of First-Line Therapy Recruiting NCT03264404 Phase 2 Pembrolizumab;Azacitidine
68 LAPTOP: Phase 1/2 Study in Locally Advanced Pancreatic Cancer to Assess Safety and Potential Efficacy of Dual Checkpoint Inhibition in Combination With Gemcitabine and Nab-paclitaxel Followed by Immune-chemoradiation. Recruiting NCT04247165 Phase 1, Phase 2 Gemcitabine;Nab-paclitaxel;Nivolumab;Ipilimumab
69 Phase 2 Gene Therapy Trial of Locally Advanced Pancreatic Adenocarcinoma Using Intratumoral Injection of CYL-02 in Combination With Gemcitabine Recruiting NCT02806687 Phase 2 Gene Therapy product CYL-02;Gemcitabine
70 Randomized Phase II Study Comparing 5FU/LV+Nal-IRI, Gemcitabine+Nab-paclitaxel or a Sequential Regimen of 2 Months 5FU/LV+Nal-IRI Followed by Two Months of Gemcitabine+Nab-paclitaxel, in Metastatic Pancreatic Cancer Recruiting NCT03693677 Phase 2 Irinotecan Liposomal Injection;5-FU/LV;Nab-Paclitaxel;Gemcitabine
71 A Phase II Study of Neoadjuvant FOLFIRINOX in Patients With Resectable Pancreatic Ductal Adenocarcinoma With Tissue Collection Active, not recruiting NCT02178709 Phase 2 FOLFIRINOX
72 A Phase II, Multi-Center, Open-Label Study of Tremelimumab Monotherapy in Patients With Advanced Solid Tumors Active, not recruiting NCT02527434 Phase 2
73 Olaparib for BRCAness Phenotype in Pancreatic Cancer: Phase II Study Active, not recruiting NCT02677038 Phase 2 Olaparib
74 Prospective Randomized Multicenter Phase II Trial to Investigate Intensified Neoadjuvant Chemotherapy in Locally Advanced Pancreatic Cancer Active, not recruiting NCT02125136 Phase 2 Gem/nab-Pac;FOLFIFINOX
75 A Study of the Safety, Immunopharmacodynamics and Anti-tumor Activity of Ibrutinib Combined With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Adenocarcinoma Active, not recruiting NCT02562898 Phase 1, Phase 2 Ibrutinib;Paclitaxel;Gemcitabine
76 A Phase 1/2, Open-Label, Safety, Tolerability, and Efficacy Study of Epacadostat in Combination With Pembrolizumab and Chemotherapy in Subjects With Advanced or Metastatic Solid Tumors (ECHO-207/KEYNOTE-723) Active, not recruiting NCT03085914 Phase 1, Phase 2 Epacadostat;Pembrolizumab;Oxaliplatin;Leucovorin;5-Fluorouracil;Gemcitabine;nab-Paclitaxel;Carboplatin;Paclitaxel;Pemetrexed;Cyclophosphamide;Carboplatin;Cisplatin;5-Fluorouracil;Investigator's choice of platinum agent
77 A Phase 1b/2 Study to Evaluate the Safety, Pharmacokinetics, and Clinical Activity of Oleclumab (MEDI9447) With or Without Durvalumab in Combination With Chemotherapy in Subjects With Metastatic Pancreatic Ductal Adenocarcinoma Active, not recruiting NCT03611556 Phase 1, Phase 2
78 A Phase Ib/II Study of Mesothelin-Targeted Immunotoxin LMB-100 Alone or in Combination With Nab-Paclitaxel in Participants With Previously Treated Metastatic and/ or Locally Advanced Pancreatic Ductal Adenocarcinoma and Mesothelin Expressing Solid Tumors Active, not recruiting NCT02810418 Phase 1, Phase 2 LMB-100;Nab-Paclitaxel
79 Preoperative Extended Chemotherapy vs. Chemotherapy Plus Hypofractionated Radiation Therapy for Borderline Resectable Adenocarcinoma of the Head of the Pancreas Active, not recruiting NCT02839343 Phase 2 mFOLFIRINOX;FOLFOX
80 A Phase II, Open Label, Randomized, Parallel Arm Study of NIS793 (With and Without Spartalizumab) in Combination With SOC Chemotherapy Gemcitabine/Nab-paclitaxel, and Gemcitabine/Nab-paclitaxel Alone in First-line Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC) Not yet recruiting NCT04390763 Phase 2 gemcitabine;nab-paclitaxel
81 The Effects of Neoadjuvant Metformin on Tumour Cell Proliferation and Tumour Progression in Pancreatic Ductal Adenocarcinoma Not yet recruiting NCT02978547 Phase 2 Metformin Hydrochloride 500Mg Tablet
82 A Multi-Cancer, Multi-State, Platform Study of Durvalumab (MEDI4736) and Oleclumab (MEDI9447) in Pancreatic Adenocarcinoma, Non-Small Cell Lung Cancer and Squamous Cell Carcinoma of the Head and Neck to Correlate Clinical, Molecular and Immunologic Parameters With DNA Methylation (DOME) Not yet recruiting NCT04262388 Phase 2
83 A Phase II Study of S-1, Irinotecan, and Oxaliplatin in Locally-Advanced Pancreatic Cancer (SIROX Study) - Followed by Curative Surgery and Adjuvant Chemotherapy Not yet recruiting NCT03316326 Phase 2 Tegafur-gimeracil-oteracil potassium;Oxaliplatin;Irinotecan
84 The Seena Magowitz Phase IB/II Trial of CMP-001 (a TLR9 Agonist) in Combination With INCAGN01949 (an Activating Anti-OX40 Antibody) for In Situ Intratumoral Injection for Patients With Stage IV Pancreatic and Other Cancers Except Melanoma Not yet recruiting NCT04387071 Phase 1, Phase 2 VLP-encapsulated TLR9 Agonist CMP-001
85 MAZEPPA: Phase II PRODIGE-GERCOR Study to Evaluate MAintenance Therapy With Olaparib or Selumetinib Plus Durvalumab According to BRCAness and KRAS Somatic Status Personalized in Metastatic Pancreatic Adenocarcinoma Patients Not yet recruiting NCT04348045 Phase 2 Arm A - Olaparib;ARM B - durvalumab plus selumetinib;ARM C FOLFIRI
86 A Phase 2A, Dose-Finding Study of Ad5.F35-hGCC-PADRE Vaccine in Adults With Gastrointestinal Adenocarcinomas at Risk of Relapse Post Definitive Surgery and Standard Therapy Not yet recruiting NCT04111172 Phase 2
87 An Open Label, Non-Randomized, Single-Center, Therapeutic Trial Examining the Feasibility, Safety, and Efficacy of FEP-BY02, a High Intensity Focused Ultrasound Tumor Treatment Device, in Patients With Pancreatic Cancer Pain Suspended NCT00637364 Phase 1, Phase 2
88 A Study of Durvalumab (MEDI4736), as an Adjuvant Therapy, Compared to Observation Alone, in Patients With Borderline Resectable Pancreatic Ductal Adenocarcinoma (BR PDA) Following Neoadjuvant Therapy and Successful Surgical Resection Terminated NCT03038477 Phase 2 Durvalumab
89 Proof of Mechanism Study of an Oral Hedgehog Inhibitor (GDC-0449) in Patients With Resectable Pancreatic Ductal Adenocarcinoma in the Pre-operative Window Period Terminated NCT01096732 Phase 2 GDC-0449
90 PHASE 1/2 STUDY OF PF-03084014 IN COMBINATION WITH GEMCITABINE AND NAB-PACLITAXEL IN PATIENTS WITH PREVIOUSLY UNTREATED METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA Terminated NCT02109445 Phase 2 PF-03084014;Gemcitabine;Nab-paclitaxel;PF-03084014;Gemcitabine;Nab-paclitaxel;Gemcitabine;Nab-paclitaxel
91 PHASE 1B/2 STUDY OF PF-04136309 IN COMBINATION WITH GEMCITABINE AND NAB-PACLITAXEL IN PATIENTS WITH PREVIOUSLY UNTREATED METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA Terminated NCT02732938 Phase 2 PF-04136309;Nab-paclitaxel;Gemcitabine
92 Intraoperative Detection of Cancer Tissue in Pancreatic Adenocarcinoma Using a VEGF-targeted Optical Fluorescent Imaging Tracer, A Multicentre Feasibility Dose Escalation Study Terminated NCT02743975 Phase 1, Phase 2 Bevacizumab-800CW
93 Phase 2 Evaluation of a Community-Based Multi-modality Management Algorithm for Clinically Non-metastatic Ductal Adenocarcinoma of the Exocrine Pancreas or Ampulla Terminated NCT02626520 Phase 2 Gemcitabine and nanoparticle albumin bound paclitaxel;5-fluorouracil and irinotecan
94 Phase 1/2 Safety and Feasibility of Gemcitabine and Nab-Paclitaxel in Combination With LDE-225 as Neoadjuvant Therapy in Patients With Borderline Resectable Pancreatic Adenocarcinoma. Terminated NCT01431794 Phase 1, Phase 2 LDE225-600mg;Gemcitabine;nab-paclitaxel;LDE225-400mg;LDE225-800mg
95 A Phase II Study of Pancreatic Enzyme Replacement (Zenpep) on Completion Rates of Adjuvant Chemotherapy Among Subjects With Resected Pancreatic Ductal Adenocarcinoma Terminated NCT03469258 Phase 2 Pancrelipase
96 Intraoperative Pancreatic Cancer Detection Using Multimodality Molecular Imaging Terminated NCT02736578 Phase 2 Cetuximab-IRDye800;Cetuximab
97 A Phase I/II, Open-Label Study to Investigate the Safety, Clinical Activity, Pharmacokinetics, and Pharmacodynamics of GSK3145095 Administered Alone and in Combination With Anticancer Agents Including Pembrolizumab in Adult Participants With Selected Advanced Solid Tumors Terminated NCT03681951 Phase 2 GSK3145095;Pembrolizumab
98 Pancreatic Resectability in Cancers With Known Limited Extension (PRICKLE) - A Single-centre Phase 2a Study of Gemcitabine Plus Nab-paclitaxel for Borderline Unresectable Locally Advanced Pancreatic Cancer Terminated NCT02124369 Phase 2 Abraxane;Gemcitabine
99 Perioperative Stromal Depletion Strategies in Pancreatic Ductal Adenocarcinoma Terminated NCT02487277 Phase 2 PEGPH20;Gemcitabine;Nab-paclitaxel
100 UPCC 10219: Phase II Study Of Stromal Changes Detected By DCE- and DW-MRI In Response To PEGPH20 Combined With Chemotherapy In Subjects With Locally-Advanced Pancreatic Cancer Withdrawn NCT04134468 Phase 2 Pegvorhyaluronidase alfa;Abraxane;Gemcitabine
101 A Phase II Open-Label Clinical Trial of CPI-613 in Combination With Modified FOLFIRINOX in Patients With Locally Advanced Pancreatic Cancer and Good Performance Status Withdrawn NCT03374852 Phase 2 CPI-613;mFOLFIRNOX
102 Phase I/II Trial of OSI-906 in Combination With Gemcitabine and Erlotinib in Patients With Metastatic Ductal Adenocarcinoma of the Pancreas Withdrawn NCT01600807 Phase 1, Phase 2 Gemcitabine, Erlotinib, OSI-906;Gemcitabine, Erlotinib
103 Study of Neoadjuvent Chemotherapy Followed by SBRT in Patients With Resectable and Borderline Resectable Pancreatic Cancer Withdrawn NCT04130399 Phase 2 FOLFIRINOX
104 A Single Arm Phase 2 Study of Gemcitabine Plus Nab-Paclitaxel in Combination With Pegvorhyaluronidase Alfa (PVHA; PEGPH20) and Pembrolizumab as Front-line Treatment for Metastatic Pancreatic Adenocarcinoma. Withdrawn NCT04045730 Phase 2 Gemcitabine
105 A Phase Ib/II Study of BGJ398 in Combination Modified FOLFIRINOX in Treatment-Naïve Metastatic Pancreatic Cancer Patients Withdrawn NCT02575508 Phase 1, Phase 2 Fluorouracil;Irinotecan Hydrochloride;Oxaliplatin;pan FGFR Kinase Inhibitor BGJ398
106 Hyperthermic Intraperitoneal Chemotherapy as Neoadjuvant Treatment for Resectable Pancreatic Adenocarcinoma: A Prospective, Phase II, Proof-of-concept Study Withdrawn NCT02850874 Phase 2 Gemcitabine
107 Phase IB/II Trial of High Dose Ascorbic Acid (AA) + Nanoparticle Paclitaxel Protein Bound + Cisplatin + Gemcitabine (AA NABPLAGEM) in Patients Who Have No Prior Therapy for Their Metastatic Pancreatic Cancer Withdrawn NCT03908333 Phase 1, Phase 2 Ascorbic Acid;Paclitaxel protein-bound;Cisplatin;Gemcitabine
108 Phase IB/II Trial of High Dose Ascorbic Acid (AA) + Nanoparticle Paclitaxel Protein Bound + Cisplatin + Gemcitabine (AA NABPLAGEM) in Patients Who Have No Prior Therapy for Their Metastatic Pancreatic Cancer Withdrawn NCT03697239 Phase 1, Phase 2 Ascorbic Acid;Paclitaxel protein-bound;Cisplatin;Gemcitabine
109 A Pilot, Prospective, Non-randomized Evaluation of the Safety of Anakinra Plus Standard Chemotherapy Regimens in Metastatic Pancreatic Ductal Adenocarcinoma Patients Unknown status NCT02021422 Phase 1 anakinra;Oxaliplatin;Irinotecan;fluorouracil
110 A Phase-1 Study Evaluating the Safety, Pharmacology and Preliminary Activity of MM-310 in Patients With Solid Tumors Unknown status NCT03076372 Phase 1 MM-310
111 Phase I Trial of the Proapoptotic Agonist, LCL161, and Gemcitabine Plus Nab-Paclitaxel in Patients With Metastatic Pancreatic Cancer Unknown status NCT01934634 Phase 1 LCL161;Gemcitabine;nab-Paclitaxel
112 A Phase 1A/1B Study of SBP-101 in Previously Treated Subjects With Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma Completed NCT02657330 Phase 1 SBP-101
113 Phase I - Escalating Dose Study of siG12D LODER (Local Drug EluteR) in Patients With Locally Advanced Adenocarcinoma of the Pancreas, and a Single Dose Study of siG12D LODER (Local Drug EluteR) in Patients With Non-operable Adenocarcinoma of the Pancreas Completed NCT01188785 Phase 1 siG12D LODER
114 Phase I Study of Chimeric Antigen Receptor Modified T Cells in Patients With Mesothelin Expressing Cancers Completed NCT02159716 Phase 1
115 Phase I Clinical Trial of Autologous Mesothelin Re-directed T Cells in Patients With Chemotherapy Refractory Metastatic Pancreatic Cancer Completed NCT01897415 Phase 1
116 A Phase Ib Study to Evaluate the Safety and Tolerability of Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Patients With Advanced Solid Tumors. Completed NCT02658214 Phase 1 paclitaxel + carboplatin;carboplatin + etoposide;gemcitabine + carboplatin;nab-paclitaxel (paclitaxel-albumin) + carboplatin;oxaliplatin + 5-fluorouracil (5FU) + leucovorin (calcium folinate/folinic acid);nab-paclitaxel (paclitaxel-albumin) + gemcitabine;cisplatin + 5-fluorouracil (5FU)
117 Pilot Trial of the NK1 Receptor Radio-Ligand [18F]SPA-RQ: Imaging Pancreatic Ductal Adenocarcinoma Completed NCT00547612 Phase 1
118 AN OPEN-LABEL PHASE IB STUDY OF PALBOCICLIB (ORAL CDK 4/6 INHIBITOR) PLUS ABRAXANE (REGISTERED) (NAB-PACLITAXEL) IN PATIENTS WITH METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA Completed NCT02501902 Phase 1 Palbociclib;Nab-Paclitaxel
119 A Phase I Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Vitamin E δ-Tocotrienol Administered to Subjects With Resectable Pancreatic Exocrine Neoplasia Completed NCT00985777 Phase 1 Vitamin E δ-Tocotrienol
120 A Dose Escalation Phase I Study With an Extension Part Evaluating the Safety and Activity of an Anti-PDL1 Antibody (DURVALUMAB) Combined With a Small Molecule CSF-1R Tyrosine Kinase Inhibitor (PEXIDARTINIB) in Patients With Metastatic/Advanced Pancreatic or Colorectal Cancers Completed NCT02777710 Phase 1 Pexidartinib;Durvalumab
121 Phase I Study of Lonsurf in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Advanced Pancreatic Ductal Adenocarcinoma (PDAC) Recruiting NCT04046887 Phase 1 Lonsurf;Gemcitabine;Nab-Paclitaxel
122 Phase 1A/1B Dose Escalation and Expansion Study of SBP-101 in Combination With Nab-Paclitaxel and Gemcitabine in Subjects With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma Recruiting NCT03412799 Phase 1 SBP-101;nab-paclitaxel;Gemcitabine Injection
123 A Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Ascending Doses of Combined Therapy With ATR Inhibitor AZD6738 and Gemcitabine, Using a Model Based Design. Recruiting NCT03669601 Phase 1 AZD6738;Gemcitabine
124 Pooled Mutant KRAS-Targeted Long Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Resected MMR-p Colorectal and Pancreatic Cancer Recruiting NCT04117087 Phase 1 KRAS peptide vaccine;Nivolumab;Ipilimumab
125 A Pilot Study of Liposomal Irinotecan Plus 5-FU / LV Combined With Paricalcitol in Patients With Advanced Pancreatic Cancer Progressed on Gemcitabine-based Therapy Recruiting NCT03883919 Phase 1 5-FU;Leucovorin;Liposomal Irinotecan;Paricalcitol
126 Phase I Trial of the Combination of PS101-Mediated Acoustic Cluster Therapy (ACT) With Chemotherapy for Treatment of Liver Metastasis In Patients With Solid Tumours With an Expansion Cohort in Metastatic Colorectal And Pancreatic Cancer Recruiting NCT04021277 Phase 1
127 Pilot Study of Mature Dendritic Cell Vaccination Against Mutated KRAS in Patients With Resectable Pancreatic Cancer Recruiting NCT03592888 Phase 1 mDC3/8-KRAS Vaccine
128 SHAPER: A Phase 1 Study of Losartan and Hypofractionated Radiation Therapy After Induction Chemotherapy for Borderline Resectable or Locally Advanced Pancreatic Cancer Recruiting NCT04106856 Phase 1 Losartan;Losartan Potassium
129 CATRIPCA - A Phase I Study of PD1 Monoclonal Antibody (Pembrolizumab) In Combination With a IAP Antagonist (Debio 1143) In (Exocrine) Pancreatic And Colorectal Non MSI-high Advanced/Metastatic Adenocarcinoma. Recruiting NCT03871959 Phase 1 Pembrolizumab;DEBIO1143
130 Study of Talimogene Laherparepvec Administered Endoscopically for the Treatment of Locally Advanced or Metastatic Pancreas Cancer Refractory to at Least One Chemotherapy Regimen Recruiting NCT03086642 Phase 1 Talimogene laherparepvec
131 A Phase I, Multicenter Dose-Escalation Study to Assess the Tolerability, Pharmacokinetics and Preliminary Anti-tumor Activity of AZD5153 in Patients With Relapsed/Refractory Malignant Solid Tumors, Including Lymphomas Recruiting NCT03205176 Phase 1 AZD5153;Olaparib
132 A Phase I Study of Mesothelin-Targeted Immunotoxin LMB-100 in Combination With Tofacitinib in Persons With Previously Treated Pancreatic Adenocarcinoma, Cholangiocarcinoma and Other Mesothelin Expressing Solid Tumors Recruiting NCT04034238 Phase 1 LMB-100;Tofacitinib
133 A Phase 1 Clinical Trial of CEND-1 in Combination With Nabpaclitaxel and Gemcitabine in Metastatic Exocrine Pancreatic Cancer Active, not recruiting NCT03517176 Phase 1 CEND-1;Nab-paclitaxel;Gemcitabine
134 Pilot Study of the Feasibility and Safety of a Personalized Peptide Vaccine in Patients With Advanced Pancreatic Ductal Adenocarcinoma or Colorectal Adenocarcinoma Active, not recruiting NCT02600949 Phase 1 Imiquimod
135 Gemcitabine and Nab-Paclitaxel Combined With the Oral Irreversible ErbB Family Blocker Afatinib in Patients With Metastatic Pancreatic Cancer: A Phase Ib Trial Active, not recruiting NCT02975141 Phase 1 Afatinib 30Mg Tab;Afatinib 40Mg Tab;Gemzar;Abraxane
136 A Phase 1, Open-Label, Dose-Finding Study Of ASN007 In Patients With Advanced Solid Tumors Active, not recruiting NCT03415126 Phase 1 ASN007: ascending doses;ASN007 RD
137 A Phase 1b Study: Treatment of Refractory Pancreatic Adenocarcinoma and Advanced Soft Tissue or Bone Sarcomas Using Decitabine Combined With Gemcitabine Active, not recruiting NCT02959164 Phase 1 Decitabine;Gemcitabine
138 Novel CCR2 PET for Pancreatic Cancer Imaging and Prediction of Response to Standard and CCR2-Targeted Therapy Active, not recruiting NCT03851237 Phase 1 64Cu-DOTA-ECLIi
139 Phase 1b Study of Vactosertib (TEW-7197) in Combination With Nal-IRI/FL in Patients With Metastatic Pancreatic Ductal Adenocarcinoma Who Have Failed First-Line Gemcitabine/Nab-Paclitaxel Not yet recruiting NCT04258072 Phase 1 Vactosertib
140 A Phase I Dose Escalation Study of Eryaspase in Combination With Modified FOLFIRINOX in Locally Advanced and Metastatic Pancreatic Ductal Adenocarcinoma Not yet recruiting NCT04292743 Phase 1 FOLFIRINOX
141 Phase I Study of Mesenchymal Stromal Cells-Derived Exosomes With KrasG12D siRNA for Metastatic Pancreas Cancer Patients Harboring KrasG12D Mutation Not yet recruiting NCT03608631 Phase 1 Mesenchymal Stromal Cells-derived Exosomes with KRAS G12D siRNA
142 A Phase 1b Study of Single Agent Idelalisib Followed by Idelalisib in Combination With Chemotherapy in Subjects With Metastatic Pancreatic Ductal Adenocarcinoma Terminated NCT02468557 Phase 1 Idelalisib;Nab-paclitaxel;mFOLFOX6
143 A Phase 1b Study Evaluating Momelotinib Combined With Capecitabine and Oxaliplatin in Subjects With Relapsed/Refractory Metastatic Pancreatic Ductal Adenocarcinoma Terminated NCT02244489 Phase 1 Momelotinib (MMB);Capecitabine;Oxaliplatin
144 Perioperative FOLFIRINOX for Patients With Resectable Pancreatic Adenocarcinoma: A Pilot Study Terminated NCT02782182 Phase 1 FOLFIRINOX (oxaliplatin, leucovorin, irinotecan)
145 To Compare the Influences of Different Methods to Remove the Pancreatic Ductal Adenocarcinoma With the Detection of Circulating Tumor Cells Unknown status NCT02451384
146 A Randomized, Double Blinding, Placebo-Controlled Clinical Trials of CD8+NKG2D+ AKT Cell Immunotherapy to the Pancreatic Cancer Patients Treated With Adjuvant Chemotherapy Unknown status NCT02929797 Early Phase 1 Gemcitabine
147 Prognostic Value of Quantitative p63 Immunostaining in Adenocarcinoma of Lung, Breast, and Pancreas Unknown status NCT01942629
148 Pilot Study Evaluating Broccoli Sprouts in Advanced Pancreatic Cancer [POUDER Trial] Unknown status NCT01879878
149 Impact of Macrophages on De-Novo Chemoresistance of Adenocarcinoma Cells Unknown status NCT01921699
150 Evaluation of Tumoral Perfusion Modification by Dynamic Imaging After Neoadjuvant Chemotherapy Combining Gemcitabine and a Hedgehog Inhibitor (Vismodegib) in Patients With Resectable Pancreatic Adenocarcinoma Unknown status NCT01713218 Early Phase 1 gemcitabine;Vismodegib
151 Evaluation of Tumoral Perfusion Modification by Dynamic Imaging After Chemotherapy Combining Gemcitabine and Nab-paclitaxel (Abraxane) in Patients With Potentially Operable, Locally Advanced or Metastatic Pancreatic Adenocarcinoma Unknown status NCT01715142 Early Phase 1 Gemcitabine;Abraxane
152 Compare More Distal Enteral Bypass With Standard Enteral Bypass in the Remission of Glucose Metabolism for Patients With Diabetes or Impaired Fasting Glucose After Pancreaticoduodenectomy: A Prospective Multicenter Randomized Clinical Trial Unknown status NCT01755273
153 A Clinical Validation Study on the Efficacy of MicroRNA-25 Level Detection in Assisting the Diagnosis of Pancreatic Cancer Unknown status NCT03432624
154 Evaluation of Safety and Feasibility of Endoscopic Ultrasound (EUS)-Guided Radiofrequency Ablation (RFA) for Solid Pancreatic Neoplasms Unknown status NCT03435770
155 Whipple at the Splenic Artery - A Procedure for Ductal Adenocarcinoma of the Pancreas With Extensive Involvement of the Porto-Mesenteric Axis: A Registry Study Completed NCT01155882
156 Diagnostic Accuracy of Circulating Tumor Cells (CTCs) and Onco-exosome Quantification in the Diagnosis of Pancreatic Cancer - PANC-CTC Completed NCT03032913
157 Minimally Invasive Detection of Lymphatic Micrometastases in Pancreatic Cancer Completed NCT00826982
158 CT Perfusion of Pancreatic Cancer and Chronic Pancreatitis: Feasibility Study Completed NCT00588367
159 Impatto Della Revisione Radiologica Con Valutazione Multidisciplinare Nella Gestione Terapeutica Dei Pazienti Affetti da Adenocarcinoma Pancreatico (PAC) Completed NCT03973736
160 Periampullary Lesions Via ERCP in Assuit University Hospital Completed NCT03185390
161 Long-term Benefit of Elderly Pancreatic Ductal Adenocarcinoma Patients After Pancreaticoduodenectomy Completed NCT03659903
162 Multicenter Retrospective Analysis for Efficacy and Safety of Second-Line Nab-Paclitaxel Plus Gemcitabine After Progression on 1st-line FOLFIRINOX in Advanced Pancreatic Ductal Adenocarcinoma Completed NCT04133155 nab paclitaxel plus gemcitabine
163 Evaluation of NGS in Combination With an Oncology Treatment Decision Support Software for Evidence-based Priorization of Individualised Treatment in Patients With Pancreatic Cancer Completed NCT02767700
164 Circulating Tumor Cells Shed in Operative Blood During Pancreatectomy for Pancreatic Cancer is Responsible for Peritoneal Recurrence Completed NCT02150746
165 Screening for Early Pancreatic Neoplasia (Cancer of the Pancreas Screening or CAPS4 Study) Completed NCT00714701
166 Pancreatic Juice Diagnosis From Duodenum Completed NCT01699698
167 Neoadjuvant FOLFIRINOX and Chemoradiation Followed by Definitive Surgery and Postoperative Gemcitabine for Patients With Borderline Resectable Pancreatic Adenocarcinoma: An Intergroup Single-Arm Pilot Study Completed NCT01821612 Early Phase 1 oxaliplatin;irinotecan;leucovorin;5-fluorouracil;capecitabine;gemcitabine
168 Relation Between Cachexia, Diabetes and periNeural Invasion in PANcreatic Cancer- Biomarkers Substudy Completed NCT03042442
169 Yield Rate for Procurement the Histologic Core With Endoscopic Ultrasound-guided Fine Needle Biopsy With 20-gauge Ultrasound Biopsy Needles for Solid Pancreatic Masses: Pilot Study Completed NCT03017599
170 Oncologic Impact of Pancreatic Fistula After Distal Pancreatectomy for Pancratic Ductal Adenocarcinoma oh the Body and the Tail : a Multicentre Retrospective Cohort Analysis / POPF-DSS (Postoperative Pancreatic Fistula - Disease Specific Survival) Completed NCT04348084
171 A Prospective Randomized Trial of Plastic vs. Covered Metal vs. Uncovered Metal Biliary Stents for the Management of Malignant Biliary Obstruction Completed NCT01038713
172 Utility of EUS-guided Microbiopsies Combined With Auxiliary Molecular Techniques in the Workup of Pancreatic Cystic Lesions Completed NCT03578445
173 PaCaReg: A Multicenter Registry Trial for the Assessement of Clinical, Epidemiological and Biological Profiles in Patients With Pancreatic Ductal Adenocarcinoma Recruiting NCT04099134
174 A Registry for BRCA Mutation Carriers With Pancreatic Ductal Adenocarcinoma Recruiting NCT01983410
175 Advancing The Local Staging Of Pancreatic Ductal Adenocarcinoma Through High-Resolution Ultrasound: A Pilot Study Recruiting NCT03820661
176 Correlation of Serum CA19-9 Levels With Levels in Saliva and Urine of Patients With Ductal Adenocarcinoma of the Pancreas Recruiting NCT02817308
177 Efficacy and Safety of Endoscopic Ultrasonography-guided Radiofrequency Ablation in Treatment of Locally Advanced, Unresectable Pancreatic Cancer Recruiting NCT04310111
178 A Phase 1, Open-Label Study Evaluating the Safety, Tolerability and Efficacy of LCAR-C182A, an Anti-Claudin18.2 CAR-T Cell Therapy in Patients With Advanced Gastric Cancer and Pancreatic Ductal Adenocarcinoma Recruiting NCT03890198 Early Phase 1
179 Ablation of Unresectable Locally Advanced Pancreatic Cancer With Nanoknife Irreversible Electroporation (IRE) System: Response and Tolerability Recruiting NCT03614910
180 Irreversible Electroporation for Locally Advanced Pancreatic Ductal Adenocarcinoma (LEAP TRIAL): A Phase I/II Prospective Trial Recruiting NCT03257150
181 Efficacy of Chemopreventive Agents on Disease-free and Overall Survival in Patients With Pancreatic Ductal Adenocarcinoma: The CAOS Study Recruiting NCT04245644
182 A Longitudinal Cohort Study to Identify Clinical and Blood Markers of Early Pancreas Cancer Recruiting NCT03568630
183 A Prospective, Multi-center Investigational Study of IMMray™ PanCan-d Diagnostic Assay for Early Detection of Pancreatic Ductal Adenocarcinoma in High-risk Populations Recruiting NCT03693378
184 Adapted Physical Activity in Patients With Resected Pancreatic Cancer (APACaPOp PRODIGE-56 Study): a National Multicenter Randomized Controlled Phase II Trial Recruiting NCT03400072
185 Imaging Biomarkers in Pancreatic and Hepatobiliary Cancers Recruiting NCT02361320
186 A Prospective Randomized Controlled Study Comparing Standard and Extended Lymphadenectomy for Pancreatic Head Cancer Recruiting NCT04115527
187 A New Scoring System for Perineural and Vascular Invasion in Pancreatic Cancer Recruiting NCT04024358
188 Evaluation and Comparison of the Growth Rate of Pancreatic Cancer Patient-derived Organoids Generated From Matched Fine Needle Aspirations (FNA) and Fine Needle Biopsies (FNB) Recruiting NCT03990675
189 Registry to Evaluate Effectiveness and Safety of the NanoKnife System for the Ablation of Stage 3 Pancreatic Adenocarcinoma Recruiting NCT03899649 SOC
190 Endoscopic Ultrasound Guided Radiofrequency Ablation (EUS-RFA) for Unresectable Pancreatic Adenocarcinoma - a Randomised Controlled Trial Recruiting NCT03772756
191 Development of Biomarkers for the Early Detection, Surveillance and Monitoring of Pancreatic Ductal Adenocarcinoma Recruiting NCT03334708
192 The Microbiome of Pancreatic Cancer: "PANDEMIC" Study Recruiting NCT04274972
193 Total Laparoscopic Pancreaticoduodenectomy Versus Open Pancreaticoduodenectomy(TJDBPS01) a Multicenter Randomized Controlled Trial Recruiting NCT03138213
194 The WASH (Water or Saline at High Volumes) Trial: A Randomized Trial to Assess the Survival Impact of Extensive Peritoneal Lavage Using Distilled WAter or Saline at High Volumes After Pancreatic Resection for Pancreatic Ductal Adenocarcinoma Recruiting NCT02757859
195 A Window of Opportunity Strategy for Targeted PARP or MEK/ERK Inhibition in Patients With Pancreatic Ductal Adenocarcinoma Recruiting NCT04005690 Early Phase 1 Cobimetinib;Olaparib
196 A Pilot Study of the Effect of Prehabilitation on Markers of Sarcopenia in Patients Undergoing Pancreatoduodenectomy for Malignant Disease Recruiting NCT03770117
197 EUS-guided Laser Complete Ablation of Advanced Pancreatic Ductal Adenocarcinoma: a Feasibility Study Recruiting NCT03784417
198 Prospectively Defining Metastatic Pancreatic Ductal Adenocarcinoma Subtypes by Comprehensive Genomic Analysis Recruiting NCT02869802
199 Bilateral Thoracoscopic Splanchnicectomy for Pain Relief in Patients With Unresectable Pancreatic Cancer Recruiting NCT03117556
200 Multicenter Prospective Randomized Controlled Clinical Trial for Comparison Between Laparoscopic and Open Distal Pancreatectomy for Ductal Adenocarcinoma of the Pancreatic Body and Tail Recruiting NCT03957135
201 Phase 1 Window of Opportunity Study of Parasympathetic Stimulation With Bethanechol in Localized Pancreatic Adenocarcinoma Prior to Surgery Recruiting NCT03572283 Early Phase 1 Bethanechol
202 Lipidomics, Proteomics, Micro RNAs and Volatile Organic Compounds Biomarkers in Bile and Serum in the Diagnosis of Malignant Biliary Strictures Recruiting NCT02531607
203 A Prospective Translational Tissue Collection Study in Early and Advanced Pancreatic Ductal Adenocarcinoma (PDAC) and Pancreatic Neuroendocrine Tumours (PanNETs) to Enable Further Disease Characterisation and the Development of Potential Predictive and Prognostic Biomarkers Recruiting NCT03840460
204 Randomized Controlled Trial for the Evaluation of Complete Microscopic Resection Margin (R0) and Lymph Node Involvement After Standard Pancreatosplenectomy (SPS) Versus Radical Anterograde Modular Pancreatosplenectomy (RAMPS) Recruiting NCT03679169
205 Preoperative Detection of Lymph Node Metastases in Pancreatic and Periampullary Carcinoma Using Ultrasmall Super Paramagnetic Iron Oxide Nanoparticle Ferumoxtran-10 Recruiting NCT04311047
206 Pancreas Disease and High Risk Registry Recruiting NCT02775461
207 Identification of Immunogenic Neo-epitopes for the Development of Personalised Pancreatic Cancer Vaccines Recruiting NCT04379960
208 Evaluation of a Novel Absorbable Radiopaque Hydrogel in Patients Undergoing Image-guided Radiotherapy for Pancreatic Adenocarcinoma Recruiting NCT03307564
209 Pancreatic Cancer Malnutrition and Pancreatic Exocrine Insufficiency in the Course of Chemotherapy in Unresectable Pancreatic Cancer Recruiting NCT04112836
210 A Research Protocol for Collection of Peripheral and Portal Vein Blood From Patients With Pancreatic Adenocarcinoma for Translational Research Recruiting NCT04289961
211 Mutation of K-RAS, CDKN2A, SMAD4 and TP53 in Pancreatic Cancer: Role of Liquid Biopsy in Preoperative Diagnosis Recruiting NCT03524677
212 Urine Trypsinogen 2 Dipstick for the Early Detection of Post-ERCP Pancreatitis Recruiting NCT03098082
213 Utilizing a Multi-gene Testing Approach to Identify Hereditary Pancreatic Cancer in Consecutive Cases Unselected for Family History Active, not recruiting NCT02790944
214 A Prospective Randomized Controlled Study Comparing Standard and Extended Lymphadenectomy for Pancreatic Head Cancer Active, not recruiting NCT02787187
215 Prospective Cohort Study Comparing Robotic and Open Surgery for Pancreatic Cancer Active, not recruiting NCT04211948
216 Identification of Predictive Plasma Biomarkers in Pancreatic Ductal Adenocarcinoma (PDAC Plasma Biomarker Study) Active, not recruiting NCT02050997
217 Evaluating in Vivo PARP-1 Expression With 18F-FluorThanatrace Positron Emission Tomography (PET/CT) in Pancreatic Cancer Active, not recruiting NCT03492164 Early Phase 1 [18F]FluorThanatrace ([18F]FTT)
218 Detection of Pancreatic Cancer and Pre-cancer by Stool DNA Testing: A Feasibility Study Active, not recruiting NCT01104129
219 Discovery of New Biomarkers in Pancreatic Cancer Using Novel Nondestructive OMICS Methodology Active, not recruiting NCT03791073
220 Prevalence of Germline Pathogenic Mutations in Patients With Pancreatic Adenocarcinoma Active, not recruiting NCT03982446
221 Application of Intrahepatic Arterial Infusion Chemotherapy for Patients With High Risk of Liver Metastases After Pancreatic Cancer Surgery Enrolling by invitation NCT03687853
222 Evaluation of CT Perfusion Parameters as a Potential Biomarker for Treatment Response in Pancreatic Cancer Enrolling by invitation NCT03012282
223 Pilot Study of a Multimodal Prehabilitation Pancreatic Cancer Program Not yet recruiting NCT03865875
224 Radical Antegrade Modular Pancreatosplenectomy Versus Standard Retrograde Pancreatosplenectomy on the Survival and Prognosis for Resectable Body and Tail Pancreatic Ductal Adenocarcinoma Not yet recruiting NCT04253847
225 A Prospective, Multi-Center Investigational Study of Heart Rate Variability Monitoring for the Early Detection of Pancreatic Cancer Not yet recruiting NCT04400903
226 Short and Long Term Outcomes of Whipples Resection in the Over 80s Not yet recruiting NCT03813368
227 The Role of Endoscopic Ultrasound Radiofrequency Ablation (EUS RFA) in the Management of Not Resectable Pancreatic Cancer. Not yet recruiting NCT04164992
228 PD-L1 and MMR Status Provided by Endoscopic Ultrasound-Guided Fine-Needle Biopsies as a Predictor of PrognosiS in Patients With Pancreatic Ductal Adenocarcinoma Not yet recruiting NCT03820921
229 Discovery of Soluble Biomarkers for Pancreatic Cancer Using Innovative All-Patient Inclusive Methodology (PanEXPEL2) Not yet recruiting NCT04370574
230 A Phase II Prospective Randomised Clinical Study of Endoscopic Ultrasound Guided Radiofrequency Ablation (EUS-RFA) for Inoperable Pancreatic Ductal Adenocarcinoma Suspended NCT03444948
231 Novel Multi-parametric MRI Techniques for Assessment of Patients With Pancreatic Ductal Adenocarcinoma Before and During Neoadjuvant Therapy Suspended NCT04306861
232 A Phase 0, Open Label Study to Evaluate the Biodistribution and Pharmacokinetics of a Single Intravenous Bolus Dose of PTP-01 in Subjects With Resectable Pancreatic Ductal Adenocarcinoma Terminated NCT01962909 Early Phase 1 PTP-01
233 A Pilot Trial of PEGPH20 (Pegylated Hyaluronidase) in Combination With Avelumab (Anti-PD-L1 MSB0010718C) in Chemotherapy Resistant Pancreatic Cancer Terminated NCT03481920 Early Phase 1 PEGylated Recombinant Human Hyaluronidase (PEGPH20);Avelumab
234 BRCA1 and BRCA2 Genetic Mutations in Mucinous Versus Nonmucinous Precursor Lesions of the Pancreas: Validation of a Mouse Model of Pancreatic Carcinogenesis Terminated NCT01103128
235 Pilot Project for Cardiopulmonary and Functional Evaluation in Patients With Pancreatic Cancer Associated Cachexia Terminated NCT02580422
236 Non-interventional Observational Post-authorization Study to Assess Clinical and Patient Reported Outcomes With Nab-paclitaxel in Combination With Gemcitabine in Routine Clinical Practice Treating Pancreatic Cancer (TRUST) Terminated NCT02670746
237 Randomized Controlled Trial Comparing Radiofrequency Ablation and Stenting vs. Stenting Alone for Biliary Obstruction Due to Unresectable Cholangiocarcinoma and Pancreatic Cancer Terminated NCT02166190
238 A Biomarker Study to Identify Predictive Signatures of Response to LDE225 (Hedgehog Inhibitor) In Patients With Resectable Pancreatic Cancer Withdrawn NCT01911416 LDE225
239 Generation of Patient Derived Pancreatic Cancer Cell Lines to Determine Mechanisms of Chemoresistance Withdrawn NCT02414100

Search NIH Clinical Center for Pancreatic Ductal Adenocarcinoma

Genetic Tests for Pancreatic Ductal Adenocarcinoma

Anatomical Context for Pancreatic Ductal Adenocarcinoma

MalaCards organs/tissues related to Pancreatic Ductal Adenocarcinoma:

40
Pancreas, T Cells, Lymph Node, Liver, Neutrophil, Testes, Lung
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Pancreatic Ductal Adenocarcinoma:
# Tissue Anatomical CompartmentCell Relevance
1 Pancreas Pancreatic Ducts Affected by disease

Publications for Pancreatic Ductal Adenocarcinoma

Articles related to Pancreatic Ductal Adenocarcinoma:

(showing 8146, show less)
# Title Authors PMID Year
1
Knockdown of microRNA-21 inhibits proliferation and increases cell death by targeting programmed cell death 4 (PDCD4) in pancreatic ductal adenocarcinoma. 61 46
21088996 2011
2
MicroRNA expression analyses in preoperative pancreatic juice samples of pancreatic ductal adenocarcinoma. 46 61
21068491 2010
3
MicroRNA-21 is induced early in pancreatic ductal adenocarcinoma precursor lesions. 46 61
20093556 2010
4
MicroRNAs in plasma of pancreatic ductal adenocarcinoma patients as novel blood-based biomarkers of disease. 61 46
19723895 2009
5
Analysis of microRNAs in pancreatic fine-needle aspirates can classify benign and malignant tissues. 61 46
18719196 2008
6
MicroRNA expression alterations are linked to tumorigenesis and non-neoplastic processes in pancreatic ductal adenocarcinoma. 46 61
17237814 2007
7
Elevated expression of microRNAs 155, 203, 210 and 222 in pancreatic tumors is associated with poorer survival. 46
19551852 2010
8
Heparan sulfate targeting strategy for enhancing liposomal drug accumulation and facilitating deep distribution in tumors. 61
32241176 2020
9
Glutamine depletion regulates Slug to promote EMT and metastasis in pancreatic cancer. 61
32510550 2020
10
Six-dimensional quantitative DCE MR Multitasking of the entire abdomen: Method and application to pancreatic ductal adenocarcinoma. 61
31961967 2020
11
Hedgehog signaling promotes angiogenesis directly and indirectly in pancreatic cancer. 61
32444947 2020
12
Triptolide inhibits pancreatic cancer cell proliferation and migration via down-regulating PLAU based on network pharmacology of Tripterygium wilfordii Hook F. 61
32464191 2020
13
Hypoxia and pancreatic ductal adenocarcinoma. 61
32380129 2020
14
Increased SPARC expression is associated with neoadjuvant therapy in resectable pancreatic ductal adenocarcinoma. 61
32548230 2020
15
Accumulation of long-chain fatty acids in the tumor microenvironment drives dysfunction in intrapancreatic CD8+ T cells. 61
32491160 2020
16
Macrophages potentiate STAT3 signaling in skeletal muscles and regulate pancreatic cancer cachexia. 61
32344015 2020
17
PAICS, a De Novo Purine Biosynthetic Enzyme, Is Overexpressed in Pancreatic Cancer and Is Involved in Its Progression. 61
32422575 2020
18
CD147 promotes DNA damage response and gemcitabine resistance via targeting ATM/ATR/p53 and affects prognosis in pancreatic cancer. 61
32456796 2020
19
Microglia in the hypothalamus respond to tumor-derived factors and are protective against cachexia during pancreatic cancer. 61
32039522 2020
20
Prometastatic secretome trafficking via exosomes initiates pancreatic cancer pulmonary metastasis. 61
32145343 2020
21
Early detection of pancreatic cancer. 61
32135127 2020
22
Proteomic Analysis of Metastasis-Specific Biomarkers in Pancreatic Cancer: Galectin-1 Plays an Important Metastatic Role in Pancreatic Cancer. 61
32413824 2020
23
The landscape of immune cell infiltration and its clinical implications of pancreatic ductal adenocarcinoma. 61
32322419 2020
24
Overexpression of MYEOV predicting poor prognosis in patients with pancreatic ductal adenocarcinoma. 61
32420813 2020
25
Fucosyltransferase 8 plays a crucial role in the invasion and metastasis of pancreatic ductal adenocarcinoma. 61
31950256 2020
26
Prognostic significance of p16 protein in pancreatic ductal adenocarcinoma. 61
32499915 2020
27
Association between aberrant dynein cytoplasmic 1 light intermediate chain 1 expression levels, mucins and chemosensitivity in colorectal cancer. 61
32319648 2020
28
The AGITG GAP Study: A Phase II Study of Perioperative Gemcitabine and Nab-Paclitaxel for Resectable Pancreas Cancer. 61
31997125 2020
29
Nitric oxide-induced stromal depletion for improved nanoparticle penetration in pancreatic cancer treatment. 61
32247201 2020
30
Long noncoding RNA SOX2OT promotes the proliferation of pancreatic cancer by binding to FUS. 61
31837005 2020
31
Resveratrol slows the tumourigenesis of pancreatic cancer by inhibiting NFκB activation. 61
32428833 2020
32
Conditional Survival After Resection for Pancreatic Cancer: A Population-Based Study and Prediction Model. 61
32052299 2020
33
Adjuvant chemotherapy in pancreatic cancer: state of the art and future perspectives. 61
32541325 2020
34
Broccoli sprout supplementation in patients with advanced pancreatic cancer is difficult despite positive effects-results from the POUDER pilot study. 61
31250356 2020
35
Efficient Gene Therapy of Pancreatic Cancer via a Peptide Nucleic Acid (PNA)-Loaded Layered Double Hydroxides (LDH) Nanoplatform. 61
32406198 2020
36
KLF7 promotes pancreatic cancer growth and metastasis by up-regulating ISG expression and maintaining Golgi complex integrity. 61
32430335 2020
37
The impact of neoadjuvant and adjuvant immunotherapy on the survival of pancreatic cancer patients: a retrospective analysis. 61
32517661 2020
38
Restoration of miR-340 controls pancreatic cancer cell CD47 expression to promote macrophage phagocytosis and enhance antitumor immunity. 61
32503944 2020
39
Use of zebrafish embryos as avatar of patients with pancreatic cancer: A new xenotransplantation model towards personalized medicine. 61
32550755 2020
40
Validation of American Joint Committee on Cancer 8th edition of TNM staging in resected distal pancreatic cancer. 61
32550043 2020
41
BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial. 61
32451495 2020
42
Combination of KRAS and SMAD4 mutations in formalin-fixed paraffin-embedded tissues as a biomarker for pancreatic cancer. 61
32314446 2020
43
Regulation of pancreatic cancer microenvironment by an intelligent gemcitabine@nanogel system via in vitro 3D model for promoting therapeutic efficiency. 61
32504777 2020
44
An unbiased high-throughput drug screen reveals a potential therapeutic vulnerability in the most lethal molecular subtype of pancreatic cancer. 61
32533886 2020
45
Clinical impact of pancreaticoduodenectomy for pancreatic cancer with resection of the secondary or later branches of the superior mesenteric vein. 61
32563216 2020
46
Expression of classical HLA class I antigens, HLA-E, and HLA-G is adversely prognostic in pancreatic cancer patients. 61
32495519 2020
47
Discovery of new targets to control metastasis in pancreatic cancer by single cell transcriptomics analysis of circulating tumor cells. 61
32499301 2020
48
Increased expression of plakoglobin is associated with upregulated MAPK and PI3K/AKT signalling pathways in early resectable pancreatic ductal adenocarcinoma. 61
32382352 2020
49
Detection of Immunotherapeutic Response in a Transgenic Mouse Model of Pancreatic Ductal Adenocarcinoma Using Multiparametric MRI Radiomics: A Preliminary Investigation. 61
32499156 2020
50
CircFOXK2 Promotes Growth and Metastasis of Pancreatic Ductal Adenocarcinoma by Complexing with RNA-Binding Proteins and Sponging MiR-942. 61
32217695 2020
51
Regional pancreatoduodenectomy versus standard pancreatoduodenectomy with portal vein resection for pancreatic ductal adenocarcinoma with portal vein invasion. 61
32191395 2020
52
Molecular Imaging of the Tumor Microenvironment Reveals the Relationship between Tumor Oxygenation, Glucose Uptake, and Glycolysis in Pancreatic Ductal Adenocarcinoma. 61
32245793 2020
53
Nicotine promotes tumor progression and epithelial-mesenchymal transition by regulating the miR-155-5p/NDFIP1 axis in pancreatic ductal adenocarcinoma. 61
32354626 2020
54
Effect of High Fructose Corn Sirup on Pancreatic Ductal Adenocarcinoma Induced by Dimethyl Benzantracene (DMBA) in Rats. 61
32475178 2020
55
Albumin-to-alkaline phosphatase ratio serves as a prognostic indicator in unresectable pancreatic ductal adenocarcinoma: a propensity score matching analysis. 61
32517802 2020
56
Glutathione S-Transferase pi-1 Knockdown Reduces Pancreatic Ductal Adenocarcinoma Growth by Activating Oxidative Stress Response Pathways. 61
32526885 2020
57
Impact of genetic variants of ABCB1, APOB, CAV1, and NAMPT on susceptibility to pancreatic ductal adenocarcinoma in Chinese patients. 61
32243098 2020
58
Diffusion-Weighted and Dynamic Contrast-Enhanced MRI Derived Imaging Metrics for Stereotactic Body Radiotherapy of Pancreatic Ductal Adenocarcinoma: Preliminary Findings. 61
32548304 2020
59
Neutrophil-lymphocyte ratio (NLR) was associated with prognosis and immunomodulatory in patients with pancreatic ductal adenocarcinoma (PDAC). 61
32510138 2020
60
Disparities in Pancreatic Ductal Adenocarcinoma-The Significance of Hispanic Ethnicity, Subgroup Analysis, and Treatment Facility on Clinical Outcomes. 61
32285629 2020
61
Safe exposure of the left renal vein during laparoscopic distal pancreatectomy for pancreatic ductal adenocarcinoma: anatomical variations and pitfalls. 61
32577883 2020
62
Expression of selected microRNAs in pancreatic ductal adenocarcinoma: is there a relation to tumor morphology, progression and patient's outcome? 61
32567937 2020
63
Pseudopterosin and O-Methyltylophorinidine Suppress Cell Growth in a 3D Spheroid Co-Culture Model of Pancreatic Ductal Adenocarcinoma. 61
32545910 2020
64
Usefulness of 18 F-fluorodeoxyglucose positron emission tomography/computed tomography for predicting the prognosis and treatment response of neoadjuvant therapy for pancreatic ductal adenocarcinoma. 61
32281301 2020
65
Toward the Clinical Development and Validation of a Thy1-Targeted Ultrasound Contrast Agent for the Early Detection of Pancreatic Ductal Adenocarcinoma. 61
32569010 2020
66
Impact of Neoadjuvant Therapy in Resected Pancreatic Ductal Adenocarcinoma of the Pancreatic Body or Tail on Surgical and Oncological Outcome: A Propensity-Score Matched Multicenter Study. 61
31848815 2020
67
Repression of the Type I Interferon Pathway Underlies MYC- and KRAS-Dependent Evasion of NK and B Cells in Pancreatic Ductal Adenocarcinoma. 61
32200350 2020
68
Assessment of Liver Metastases Using CT and MRI Scans in Patients with Pancreatic Ductal Adenocarcinoma: Effects of Observer Experience on Diagnostic Accuracy. 61
32503262 2020
69
Phase 1b study of a small molecule antagonist of human chemokine (C-C motif) receptor 2 (PF-04136309) in combination with nab-paclitaxel/gemcitabine in first-line treatment of metastatic pancreatic ductal adenocarcinoma. 61
31297636 2020
70
Letter to the editor regarding "Variant anatomy of the biliary system as a cause of pancreatic and peri-ampullary cancers." 61
32563595 2020
71
The Golgi: Keeping It Unapologetically Basic. 61
32482665 2020
72
Molecular Targeting of Cancer-Associated PCNA Interactions in Pancreatic Ductal Adenocarcinoma Using a Cell-Penetrating Peptide. 61
32368614 2020
73
Prooxidative activity of plumbagin induces apoptosis in human pancreatic ductal adenocarcinoma cells via intrinsic apoptotic pathway. 61
32027944 2020
74
R269C variant of ESR1: high prevalence and differential function in a subset of pancreatic cancers. 61
32513126 2020
75
SST gene hypermethylation acts as a pan-cancer marker for pancreatic ductal adenocarcinoma and multiple other tumors: toward its use for blood-based diagnosis. 61
32243066 2020
76
In silico identification of therapeutic compounds against microRNA targets in drug-resistant pancreatic ductal adenocarcinoma. 61
32579088 2020
77
Biomarker Panel for the Diagnosis of Pancreatic Ductal Adenocarcinoma. 61
32492943 2020
78
Overexpression of YBX1 Promotes Pancreatic Ductal Adenocarcinoma Growth via the GSK3B/Cyclin D1/Cyclin E1 Pathway. 61
32300640 2020
79
Identification of key lncRNAs in the tumorigenesis of intraductal pancreatic mucinous neoplasm by coexpression network analysis. 61
32239802 2020
80
LINC01133: an emerging tumor-associated long non-coding RNA in tumor and osteosarcoma. 61
32556990 2020
81
Pancreas Solid Tumors. 61
32402301 2020
82
Genotype-phenotype correlations for pancreatic cancer risk in Dutch melanoma families with pathogenic CDKN2A variants. 61
32482799 2020
83
An Immunocompetent Model of Pancreatic Cancer Resection and Recurrence. 61
32542554 2020
84
Association of Glycated Hemoglobin Levels With Risk of Pancreatic Cancer. 61
32530471 2020
85
Autophagy Inhibition Synergizes with Immunotherapy in Pancreatic Cancer. 61
32357992 2020
86
The Peptide Hormone Cholecystokinin Links Obesity to Pancreatic Cancer. 61
32357993 2020
87
Resolving the HIF paradox in pancreatic cancer. 61
32512024 2020
88
The Prognostic Index Independently Predicts Survival in Patients with Pancreatic Ductal Adenocarcinoma Undergoing Resection. 61
31900809 2020
89
Clinicopathologic Features and Outcomes of Early-Onset Pancreatic Adenocarcinoma in the United States. 61
31894482 2020
90
Role of imaging biomarkers for prognostic prediction in patients with pancreatic ductal adenocarcinoma. 61
32037002 2020
91
Loss of heterozygosity for KrasG12D promotes REDD1-dependent, non-canonical glutamine metabolism in pancreatic ductal adenocarcinoma. 61
32279996 2020
92
Implementation of contemporary chemotherapy for patients with metastatic pancreatic ductal adenocarcinoma: a population-based analysis. 61
32056483 2020
93
Genome-wide transcriptome profiling of ex-vivo precision-cut slices from human pancreatic ductal adenocarcinoma. 61
32493953 2020
94